Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)

European Journal of Cancer

Volumn 44, Issue 1, 2008, Pages 25-29

  Booth, Christopher M ^a   Calvert, A Hilary ^b   Giaccone, Giuseppe ^c   Lobbezoo, Marinus W ^d   Eisenhauer, Elizabeth A ^a   Seymour, Lesley K ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NDDO Research Foundation   (Netherlands)

Author keywords

Clinical trials phase II; Drug therapy; Growth factors antagonists; Inhibitors; Neoplasms; Receptors

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC AGENT;

ARTICLE; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; HUMAN; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS DESIGN;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASMS; THERAPIES, INVESTIGATIONAL;

EID: 37149053580     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.031     Document Type: Article

References (13)

1. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints in phase I studies of targeted anticancer therapy: report of the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 2007, in press.
2. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 7035 (2005) 913-917
3. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
4. Dent S., Zee B., Dancey J., Hanauske A., Wanders J., and Eisenhauer E. Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol 19 3 (2001) 785-791
5. Rubinstein L.V., Korn E.L., Freidlin B., Hunsberger S., Ivy S.P., and Smith M.A. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23 28 (2005) 7199-7206
6. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 16 (2006) 2505-2512
7. Byrne M.J., and Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 2 (2004) 257-260
8. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 25 13 (2007) 1760-1764
9. Redman M., and Crowley J. Small randomized trials. J Thorac Oncol 2 1 (2007) 1-2
10. Rosner G.L., Stadler W., and Ratain M.J. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20 22 (2002) 4478-4484
11. Freidlin B., and Simon R. Evaluation of randomized discontinuation design. J Clin Oncol 23 22 (2005) 5094-5098
12. Berry D.A. Bayesian clinical trials. Nat Rev Drug Discov 5 1 (2006) 27-36
13. Giles F.J., Kantarjian H.M., Cortes J.E., et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 21 9 (2003) 1722-1727